Skip to main content
. 2023 May 17;34(9-10):430–438. doi: 10.1089/hum.2022.081

Figure 5.

Figure 5.

AAV seroprevalence in study participants based on ambulatory status. (A) Overall seroprevalence rates for AAV2, AAV8, AAV9, and AAVrh74 NAbs in the study cohort grouped based on ambulatory status: ambulatory, n = 48, and nonambulatory, n = 46, for AAV2 and AAV9 analysis. Ambulatory, n = 43, and nonambulatory, n = 43, for AAV8 and AAVrh74 analysis. (B) Average NAb titers for indicated serotypes for ambulatory and nonambulatory participants. Note that only participant samples with NAb titers >1:5 were used for the analysis; *p < 0.05 based on unpaired Student's t-test. All other comparisons are not significant.